Virtual Conference
Programme draft 19/10/2020

1st Translational Research E-Conference: Chronic Lymphocytic Leukaemia
November 16-19, 2020
Chairs: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

This program is presented according to Central European Time (CET).
Please check the corresponding hours in your time zone.

Monday, November 16, 2020

13:50-14:00 Welcome

SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences
Chairs: Jennifer Brown (Boston), Christopher Oakes (Columbus)

14:00-14:05	Introduction	Jennifer Brown (Boston) Christopher Oakes (Columbus)
14:05-14:20	Genetic predisposition	Jennifer Brown (Boston)
14:20-14:35	Genetic landscape	Cathy Wu (Boston)
14:35-14:50	Ibrutinib resistance	Jennifer Woyach (Colombus)
14:50-15:05	Epigenetic landscape	Christopher Oakes (Columbus)
15:05-15:20	Risk stratification in CLL	Antonio Cuneo (Ferrara)
15:20-15:50	*General Discussion*	

SESSION II – The role of BCR activation and signalling for CLL
Chairs: Paolo Ghia (Milan), Kostas Stamatopoulos (Thessaloniki)

15:50-15:55	Introduction	Paolo Ghia (Milan) Kostas Stamatopoulos (Thessaloniki)
15:55-16:10	BCR isotypes/autonomous signalling	Hassan Jumaa (Ulm)
16:10-16:25	The latest news on stereotypes	Kostas Stamatopoulos (Thessaloniki)
16:25-16:40	Novel BCR targets	Andrew Steele (Southampton)
16:40-16:55	Next generation BTK inhibitors (covalent/non-covalent?)	Anthony Mato (New York)

SHORT ORAL COMMUNICATION

16:55-17:02 *Mutational landscape of CLL mice models overexpressing aid identify proliferative-associated tumor genes involved in leukemic progression* — Pablo Oppezzo (Montevideo)

17:02- 17:32 General discussion

17:35-18:35 *Clinical Poster Walk*
Leaders: Matthew Davids (Boston), Alessandra Tedeschi (Milan)

18:30-19:30 Possible slot for a satellite symposium

SESSION III – Therapeutic options for CLL
Chairs: Alain Delmer (Reims)*, Michael Hallek (Cologne)

20:30-20:35	Introduction	Alain Delmer (Reims) Michael Hallek (Cologne)
20:35-20:50	Ibrutinib for everybody	Jennifer Woyach (Columbus)
20:50-21:05	Ibrutinib for a small subgroup only	Florence Cymbalista (Bobigny)
21:05-21:20	MURANO and MRD	John Seymour (Melbourne)
21:20-21:35	CLL14 update	Kirsten Fischer (Cologne)

SHORT ORAL COMMUNICATION

21:35-21:42 *Neddylation pathway regulates treg differentiation and T-cell function in Chronic Lymphocytic Leukemia ex vivo and murine in vivo studies* — Scott Best (Portland)

21:42-22:12 General Discussion

Tuesday, November 17, 2020

13:00-14:00 Simultaneous Lunchtime Meet the Expert sessions

1. Prognostic and predictive markers — Barbara Eichhorst (Cologne)
2. First line therapy: continuous or time limited treatment? — Michael Hallek (Cologne)

SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)
Chairs: Jennifer Woyach (Columbus)

14:05-14:10	Introduction	Jennifer Woyach (Columbus)
14:10-14:25	Ibrutinib trials	Alessandra Tedeschi (Milan)
14:25-14:40	Ibrutinib real world	Loïc Ysebaert (Toulouse)
14:40-14:55	Venetoclax trials	Matthew Davids (Boston)
14:55-15:10	Venetoclax / PI3K real world	Anthony Mato (New York)

SHORT ORAL COMMUNICATION

15:10-15:17 *Sequential treatment with bendamustine, obinutuzumab (GA101) and ibrutinib in Chronic Lymphocytic Leukemia: final results of the CLL2-BIG trial of the German CLL study group (GCLLSG)* — Julia von Tresckow (Essen)

15:17-15:45 *General discussion*

15:50-16:50 **SATELLITE SYMPOSIUM:**
Utilization of MRD assessment in the clinical management of CLL patients

Chair: Barbara Eichhorst (Cologne)
Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)

This symposium is organised and funded by Adaptive Biotechnologies.

16:50-17:50 **Meet the Expert session**
Resistance to ibrutinib: what to do — Jennifer Brown (Boston)

16:50-17:50 Biology Poster Walk:
Leaders: Alexey Danilov (Duarte), Davide Rossi (Bellinzona)

Wednesday, November 18, 2020

SESSION V – The increasing role of the leukaemic microenvironment
Chairs: Silvia Deaglio (Turin), Adrian Wiestner (Bethesda)

14:30-14:35 Introduction — Silvia Deaglio (Turin), Adrian Wiestner (Bethesda)

14:35-14:50 Role of stromal cells — Andrea Brendolan (Milan)

14:50-15:05 Hypoxia, metabolic reprogramming and immunosuppression occurring in CLL niche — Silvia Deaglio (Turin)

15:05-15:20 Role of T cells — Arnon Kater (Amsterdam)

15:20-15:35 Immunomodulatory effects of kinase inhibitors — Adrian Wiestner (Bethesda)

SHORT ORAL COMMUNICATION

15:35-15:42 *Expansion of antitumor cytotoxic CD8+ T cells in CLL patients treated with ibrutinib* — Maria Joao Baptista (Badalona)

15:42-16:12 *General discussion*

SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL
Chairs: Matthew Davids (Boston), Peter Dreger (Heidelberg)

16:15-16:20	Introduction	Matthew Davids (Boston) Peter Dreger (Heidelberg)
16:20-16:35	Next generation PI3K inhibitors	Peter Hillmen (Leeds)
16:35-16:50	Novel inhibitors at preclinical level (MCL1 & CDK inhibitors)	Alexey Danilov (Duarte)
16:50-17:05	Mechanistic effects of BH3 Mimetics in CLL	Eric Eldering (Amsterdam)
17:05-17:20	CAR-T cells	Stephen Schuster (Philadelphia)
17:20-17:35	Allo-transplant	Peter Dreger (Heidelberg)
17:35-18:05	*General discussion*	

SESSION VII – Efficacy through safety
Chairs: Barbara Eichhorst (Cologne), John Seymour (Melbourne)

18:05-18:10	Introduction	Barbara Eichhorst (Cologne)
18:10-18:25	Cardiologist	Javid Moslehi (Nashville)
18:25-18:40	Dermatologist	Nicole LeBoeuf (Boston)
18:40-18:55	Infectious diseases	Pierluigi Viale (Bologna)
18:55-19:10	Gastroenterology	Stefano Fagiuoli (Bergamo)
19:10-19:40	*General discussion*	

Thursday, November 19, 2020

12:00-13:00 Simultaneous Lunchtime Meet the Expert sessions

1. Treatment of relapsed CLL	Paolo Ghia (Milan)
2. Management of novel drugs side effect	Carol Moreno (Barcelona)
3. MRD assessment	Andrew Rawstron (Leeds)

SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance
Chairs: Davide Rossi (Bellinzona), John Seymour (Melbourne)

13:00-13:05	Introduction	Davide Rossi (Bellinzona) John Seymour (Melbourne)
13:05-13:20	Clonal evolution	Davide Rossi (Bellinzona)
13:20-13:35	PI3K	Jennifer Brown (Boston)
13:35-13:50	Venetoclax	John Seymour (Melbourne)

SHORT ORAL COMMUNICATIONS

13:50-13:57	*Aid-mediated mechanisms of resistance to BCR inhibitors in Chronic Lymphocytic Leukemia (CLL)*	Chiara Pighi (Turin)
13:57-14:04	*NOTCH2 contributes to venetoclax resistance in Chronic Lymphocytic Leukemia*	Stefania Fiorcari (Modena)
14:04-14:35	*General discussion*	
14:35-14:45	***Coffee break***	

SESSION IX – Contrasting therapeutic concepts
Chairs: Jennifer Brown (Boston), Michael Hallek (Cologne)

14:45-14:50	Introduction	Jennifer Brown (Boston) Michael Hallek (Cologne)
14:50-15:05	MRD as a dynamic endpoint	Peter Hillmen (Leeds)
15:05-15:20	Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL	David M. Kurtz (Stanford)
15:20-15:35	Sequential vs combination treatments	William Wierda (Houston)
15:35-15:50	Time limited vs continuous treatments	Barbara Eichhorst (Cologne)
15:50-16:20	*General discussion*	
16:20-16:30	*Closing Remarks*	

MEETING CLOSURE

**pending*